Effects of carvadilol on oxidative stress in human endothelial cells and healthy volunteers

European Journal of Clinical Pharmacology

Volumn 60, Issue 2, 2004, Pages 83-88

  Fahlbusch, Stefanie A ^a   Tsikas, Dimitrios ^a   Mehls, Christina ^a   Gutzki, Frank Mathias ^a   Böger, Rainer H ^b   Frölich, Jürgen C ^a   Stichtenoth, Dirk O ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Carvedilol; Isoprostanes; Oxidative stress

Indexed keywords

2,3 DINOR 5,6 DIHYDRO 8 ISOPROSTAGLANDIN F2 ALPHA; 3 NITROTYROSINE; 8 ISOPROSTAGLANDIN F2 ALPHA; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; ISOPROSTANE DERIVATIVE; METOPROLOL; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; 2,3 DINOR 5,6 DIHYDRO 8 ISO PROSTAGLANDIN F2(ALPHA); 2,3-DINOR-5,6-DIHYDRO-8-ISO-PROSTAGLANDIN F2(ALPHA); 3-NITROTYROSINE; 8 ISOPROSTAGLANDIN E2; 8-ISOPROSTAGLANDIN E2; ADRENERGIC RECEPTOR BLOCKING AGENT; BM 910228; CARBAZOLE DERIVATIVE; DRUG DERIVATIVE; LOW DENSITY LIPOPROTEIN; PROPANOLAMINE DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TYROSINE;

ADULT; ANALYTICAL PARAMETERS; ANTIOXIDANT ACTIVITY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD LEVEL; BLOOD PRESSURE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIUM CELL; GAS CHROMATOGRAPHY; HEART RATE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TANDEM MASS SPECTROMETRY; URINARY EXCRETION; CELL CULTURE; METABOLISM;

ADRENERGIC ANTAGONISTS; ADULT; ANTIOXIDANTS; CARBAZOLES; CELLS, CULTURED; CROSS-OVER STUDIES; DINOPROST; DINOPROSTONE; DOUBLE-BLIND METHOD; ENDOTHELIAL CELLS; HUMANS; ISOPROSTANES; LIPOPROTEINS, LDL; MALE; METOPROLOL; OXIDATIVE STRESS; PROPANOLAMINES; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TYROSINE;

EID: 2442683144     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0729-0     Document Type: Article

References (35)

1. Yue T-L, McKenns PJ, Lysko PG, Gu JL, Lysko KA, Ruffolo RR, Feuerstein GZ (1994) SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant. Eur J Pharmacol 251:237-243
2. Feuerstein G, Shusterman NH, Ruffolo RR (1997) Carvedilol update IV: prevention of oxidative stress, cardiac remodeling and progression of congestive cardiac failure. Drugs Today 33:453-473
3. Aruoma OI (1997) Scavenging of hypochlorous acid by carvedilol and ebselen in vitro. Gen Pharmacol 28:269-272
4. Maggi E, Marchesi E, Covini D, Negro C, Perani G, Bellomo G (1996) Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 27:532-538
5. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, De Angelis L, D'Onofrio F (1997) Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 126:955-959
6. Dandona P, Karne R, Ghanim H, Hamouda W, Aljada A, Magsino CH Jr (2000) Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 101:122-124
7. Arumanayagam M, Chan S, Tong S, Sanderson JE (2001) Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. J Cardiovasc Pharmacol 37:48-54
8. Gutteridge JMC, Halliwell B (1990) The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem Sci 15:129-135
9. Roberts LJ, Morrow JD (2002) Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation. Cell Mol Life Sci 59:808-820
10. Halliwell B (1997) What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite in vivo? FEBS Lett 411:157-160
11. 2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 17:3230-3235
12. 2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler Thromb Vase Biol 17:3236-3241
13. 2α in humans. J Biol Chem 271:20617-20620
14. Beckman JS, Ischiropoulos H, Zhu L, van der Woerd M, Smith C, Chen J, Harrison J, Martin JC, Tsai M (1992) Kinetics of superoxide dismutase and iron catalyzed nitration of phenolics by peroxynitrite. Arch Biochem Biophys 298:438-45
15. Beckmann JS, Ye YZ, Anderson PG, Chen J, Accavitti MA, Tarpey MM, White CR (1994) Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler 375:81-88
16. Esterbauer H, Striegl G, Puhl H, Rotheneder M (1989) Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 6:67-75
17. 2α in human urine. J Chromatogr B 744:99-112
18. Schwedhelm E, Tsikas D, Gutzki F-M, Frölich JC (1999) Gas chromatographic-tandem mass spectrometric quantification of free 3-nitrotyrosine in human plasma at the basal state. Anal Biochem 276:195-203
19. Cordova C, Musca A, Violi F, Alessandri C, Ghiselli A, Luliano L, Balsano F (1984) Influence of vitamin E on plasma malondialdehyde-like material in man. Thromb Haemostas 51:347-348
20. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with folin phenol reagent. J Biol Chem 193:265-275
21. Hills M, Armitage P (1979) The two-period cross-over clinical trials. Br J Clin Pharmacol 8:7-20
22. Lysko PG, Webb CL, Gu JL, Ohlstein EH, Ruffolo RR Jr, Yue TL (2000) A comparison of carvedilol and metoprolol antioxidant activities in vitro. J Cardiovasc Pharmacol 36:277-281
23. Rössig L, Haendeler J, Mallat Z, Hugel B, Freyssinet J-M, Tedgui A, Dimmeler S, Zeiher AM (2000) Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol 36:2081-2089
24. Flesch M, Maack C, Cremers B, Baumer AT, Sudkamp M, Bohm M (1999) Effect of β-blockers on free radical-induced cardiac contractile dysfunction. Circulation 100:346-353
25. Lopez BL, Christopher TA, Yue TL, Ruffolo R, Feuerstein GZ, Ma XL (1995) Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical induced endothelial dysfunction. Pharmacology 51:165-173
26. Louis WJ, McNeil JJ, Workman BS (1987) A pharmacokinetic study of carvedilol in elderly subjects: preliminary report. J Cardiovasc Pharmacol 10:89-93
27. Cargnoni A, Ceconi C, Bernocchi P, Boraso A, Parrinello G, Curello S, Ferrari R (2000) Reduction of oxidative stress by carvedilol: role in maintenance of ischaemic myocardium viability. Cardiovasc Res 47:556-566
28. Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz-Varley C, Ocampo O, Eng C (1999) Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99:2645-2651
29. The Heart Outcomes Prevention Evaluation Study Investigators (2000) Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 342:154-160
30. Minuz P, Patrignani P, Gaino S, Degan M, Menapace L, Tommasoli R, Seta F, Capone ML, Tacconelli S, Palatresi S, Bencini C, Del Vecchio C, Mansueto G, Arosio E, Santonastaso CL, Lechi A, Morganti A, Patrono C (2002) Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 106:2800-2805
31. 2α. Possible methodological, mechanistic and clinical implications. J Chromatogr B 794:237-255
32. Troost R, Schwedhelm E, Rojczyk S, Tsikas D, Frölich JC (2000) Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol 50:377-379
33. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150-1155
34. Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, Taylor PR, Heinonen OP (1997) Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 349:1715-1720
35. Serruys PW, Foley DP, Höfling B, Fuel J, Glogar HD, Seabra-Gomes R, Goicolea J, Coste P, Rutsch W, Katus H, Bonnier H, Wijns W, Betriu A, Hauf-Zachariou U, van Swijndregt EM, Melkert R, Simon R (2000) Carvedilol for prevention of restenosis after directional coronary atherectomy: final results of the European carvedilol atherectomy restenosis (EURO-CARE) trial. Circulation 101:1512-1522